Karuna Therapeutics (Nasdaq:KRTX) - Cotización, noticias y análisis

Resumen de acción KRTX

Karuna Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que crea y suministra medicamentos transformadores para personas con enfermedades psiquiátricas y neurológicas.

Acerca de la empresa

KRTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 78% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 60.07%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($654K)

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Karuna Therapeutics, Inc.

Incyte

NasdaqGS:INCY

US$12.1b

United Therapeutics

NasdaqGS:UTHR

US$11.6b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$15.6b

Exact Sciences

NasdaqCM:EXAS

US$11.6b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Karuna Therapeutics
Historical stock prices
Current Share Price	US$329.83
52 Week High	US$329.99
52 Week Low	US$158.38
Beta	1.15
1 Month Change	3.64%
3 Month Change	50.58%
1 Year Change	80.73%
3 Year Change	169.65%
5 Year Change	n/a
Change since IPO	1,547.50%

Noticias y actualizaciones recientes

Recent updates

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Feb 20

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06

Best Performing Stocks

Sep 23

Karuna Therapeutics: This Ship Has Sailed

Sep 09

Karuna Therapeutics GAAP EPS of -$2.17 misses by $0.10, revenue of $5.28M

Aug 08

Karuna Therapeutics: Front-Running KarXT Phase 3

Jun 26

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10

Rentabilidad de los accionistas

	KRTX	US Biotechs	Mercado US
7D	3.3%	4.4%	0.6%
1Y	80.7%	2.8%	23.9%

Rentabilidad vs. Industria: KRTX superó al sector US Biotechs , que obtuvo un rendimiento del -3.7% el año pasado.

Rentabilidad vs. Mercado: KRTX superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is KRTX's price volatile compared to industry and market?
KRTX volatility
KRTX Average Weekly Movement	13.9%
Biotechs Industry Average Movement	11.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de KRTX ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de KRTX ha aumentado de 8% a 14% en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	339	Bill Meury	www.karunatx.com

Karuna Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica que crea y suministra medicamentos transformadores para personas con enfermedades psiquiátricas y neurológicas. Su principal producto candidato es KarXT, un modulador oral de los receptores muscarínicos para el tratamiento de la psicosis aguda en pacientes con esquizofrenia; y para el tratamiento de trastornos del sistema nervioso central, como los síntomas negativos y cognitivos de la esquizofrenia y la psicosis, así como para el tratamiento de diversos tejidos periféricos y la psicosis relacionada con la demencia, incluida la enfermedad de Alzheimer. La empresa también se centra en el desarrollo de otros candidatos a fármacos dirigidos a los muscarínicos; y pretende desarrollar la candidatura principal TRPC4/5 y KAR-2618 para el tratamiento del trastorno depresivo.

Resumen de fundamentos de Karuna Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Karuna Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de KRTX
Capitalización bursátil	US$12.58b
Beneficios(TTM)	-US$433.68m
Ingresos (TTM)	US$654.00k

Over9,999x

Ratio precio-ventas (PS)

-29.0x

Ratio precio-beneficio (PE)

¿Está KRTX sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de KRTX
Ingresos	US$654.00k
Coste de los ingresos	US$0
Beneficio bruto	US$654.00k
Otros gastos	US$434.33m
Beneficios	-US$433.68m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-11.37
Margen bruto	100.00%
Margen de beneficio neto	-66,311.93%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado KRTX a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción KRTX

Recompensas

Análisis de riesgos

Competidores de Karuna Therapeutics, Inc.

NasdaqGS:INCY

US$12.1b

NasdaqGS:UTHR

US$11.6b

NasdaqGS:BMRN

US$15.6b

NasdaqCM:EXAS

US$11.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Recent updates

Karuna Therapeutics, Inc. Files Form 15

Karuna Therapeutics, Inc.(NasdaqGM:KRTX) dropped from NASDAQ Composite Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Karuna Therapeutics, Inc. (NasdaqGM:KRTX) from Capital International Investors, FMR LLC, The Vanguard Group, Inc., T. Rowe Price Group, Inc. (NasdaqGS:TROW) and others.

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates increase by 11%, EPS downgraded

Board Member exercised options to buy US$9.9m worth of stock.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Karuna Therapeutics: Getting Sold Short

Chief Medical Officer notifies of intention to sell stock

Price target increased by 7.2% to US$327

Karuna Therapeutics, Inc. Announces Resignation of Steve Paul as Chief Scientific Officer and President of Research and Development

Chief Medical Officer notifies of intention to sell stock

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 23%

Consensus revenue estimates decrease by 22%

Price target increased by 9.9% to US$291

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.6 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive merger agreement to acquire Karuna Therapeutics, Inc. (NasdaqGM:KRTX) for $12.5 billion.

Karuna Therapeutics, Inc. Announces The Lancet Publication of Data from Phase 3 EMERGENT-2 Trial Evaluating KarXT in Schizophrenia

New minor risk - Profitability

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for Karxt for the Treatment of Schizophrenia

Karuna Therapeutics, Inc. Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates decrease by 55%

New minor risk - Profitability

Third quarter 2023 earnings released: US$3.16 loss per share (vs US$2.38 loss in 3Q 2022)

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2023 Neuroscience Education Institute Congress

Karuna Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for Karxt for the Treatment of Schizophrenia

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Director exercised options and sold US$2.5m worth of stock

New minor risk - Profitability

Karuna Therapeutics, Inc. Announces Chief Financial Officer Changes

Director exercised options and sold US$2.6m worth of stock

Karuna Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Director notifies of intention to sell stock

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

CFO & Secretary notifies of intention to sell stock

Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting

Consensus revenue estimates increase by 20%

Co-Founder & COO notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Independent Director exercised options and sold US$96k worth of stock

Chief Medical Officer exercised options and sold US$920k worth of stock

Consensus revenue estimates fall by 85%

CFO & Secretary notifies of intention to sell stock

Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Chief Medical Officer notifies of intention to sell stock

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer

Independent Director exercised options and sold US$113k worth of stock

CFO & Secretary exercised options to buy US$2.3m worth of stock.

Chief Medical Officer exercised options and sold US$965k worth of stock

Karuna Therapeutics, Inc. Announces Executive Changes, Effective January 3, 2023

Co-Founder & COO exercised options and sold US$168k worth of stock

Chief Medical Officer notifies of intention to sell stock

Consensus revenue estimates fall by 25%

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Co-Founder & COO exercised options and sold US$444k worth of stock